Plaque Psoriasis
Conditions
Brief summary
This study is to evaluate the efficacy and safety of M518101 and the dose relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients.
Detailed description
This study is to evaluate the efficacy and safety of M518101 and the dose response relationship among two doses of M518101 and placebo in male and female plaque psoriasis patients and to confirm the persistence of the effect of M518101.
Interventions
DRUGM518101
Proper quantity twice a day
DRUGplacebo
Proper quantity twice a day
DRUGDovonex
Proper quantity twice a day
Sponsors
Maruho Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Who are able and willing to give signed informed consent 2. Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator. 3. Who have less than 20% of body surface area (BSA) afflicted with plaques 4. Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study.
Exclusion criteria
1. Who have a history of allergy to vitamin D3 derivative preparations. 2. Who have a history of relevant drug hypersensitivity. 3. Who have a history of contact dermatitis induced by a topical medicine. 4. Who are pregnant or lactating. 5. Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease. 6. Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests. 7. Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study. 8. Whose serum calcium levels exceed the upper limit of reference range 9. Who have used any investigational medicinal product and/or participated in any clinical study within 60 days before the day of signing the ICF. 10. Who have been treated with systemic therapy within 2 weeks before the day of signing the ICF and during the wash-out period. 11. Who have been treated with biologics within 5 half-lives of the biologics before the day of randomization. 12. Who have been treated with topical therapy during the wash-out period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| severity of plaque psoriasis | 8 weeks after dosing |
Secondary
| Measure | Time frame |
|---|---|
| Investigator global assessment | 8 weeks after dosing |
Countries
United States
Outcome results
None listed